pcDNA3.1-rpfB, pcDNA3.1-rpfD
The candidate vaccine we are developing is a recombinant plasmid DNA vaccine. Two genes from the rpfs family, namely rpfB and rpfD, were inserted full-length into the pcDNA3.1 plasmid along with the Kozak sequence, resulting in recombinant plasmids pcDNA3.1-rpfB and pcDNA3.1-rpfD. The vaccination method used on test animals is intramuscular injection of the recombinant plasmid…
Read MoreTBvac-1, TBvac-2, TBvac-10
TBvac-1, TBvac-2, and TBvac-10 use a recombinant tri-segmented Pichinde virus (PICV) vector (rP18tri) to express M. tuberculosis antigens. TBvac-1 and TBvac-2 encode Ag85B, EsxA/ESAT-6, and EsxH/TB10.4, with antigen locations swapped between S1 and S2 segments. TBvac-10 encodes Ag85B, EsxH/TB10.4, RpfA, and Rv1733c. Vaccine stocks are produced in BHK-21 cells from plaque purified virus.
Read MoreBCG-EVs
This vaccine comprises EVs derived from Mycobacterium bovis and Escherichia coli Nissle 1917. BCG-EVs carry multiple molecules, including known protective TB antigens. The EVs will be lyophilized to ensure physicochemical stability and eliminate the need for a cold chain. Owing to their acellular nature, the vaccine is suitable for infants and children, including those living…
Read MoreTri:ChAd:TB
Tri:ChAd:TB is built on the chimpanzee adenovirus serotype 68 vector, expressing Ag85A, TB10.4, and RpfB. These antigens spanning distinct M.tb life-cycle stages. Ag85A wanes after acute infection, whereas TB10.4 remains highly expressed. RpfB is upregulated during dormancy and resuscitation. This vaccine is formulated for respiratory mucosal delivery.
Read MorePNx6
PNx6 is a modular, self-assembling and self-adjuvanting peptide-based vaccine candidate that is cold-chain independent. Each peptide building blocks consist of a linear arrangement comprising a 15-leucine (15L) self-assembly inducer moiety, a 15 amino acid Mtb epitope and a 9 amino acids HLA-E binding moiety, with each moiety separated by a triple lysine spacer.
Read More